Capula Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Capula Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-4,504	Closed	-$371K	–	500
2024 Q2	$371K	Buy	+4,504	New	+$375K	﹤0.01%	336
2021 Q4	–	Sell	-2,689	Closed	-$208K	–	258
2021 Q3	$208K	Sell	2,689 -261	-9%	-$20.6K	﹤0.01%	787
2021 Q2	$246K	Buy	+2,950	New	+$234K	﹤0.01%	636

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Capula Management's BMRN Position: Q3 2024 in Review

Capula Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 4,504 shares — an estimated $371K sold.

Capula Management first reported a position in BMRN in Q2 2021 and held it in 3 quarters. The position peaked at $371K in Q2 2024. 553 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

Capula Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Capula Management sold 4,504 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $371K.
Capula Management first reported a position in BioMarin Pharmaceuticals in Q2 2021 and held it in 3 quarters.
Capula Management's BioMarin Pharmaceuticals position peaked at $371K in Q2 2024.
553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on Capula Management's 13F filing for Q3 2024, filed 13 Nov 2024.